Novo Nordisk (NVO, NOVO-B.CO) said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36bn Danish crowns (£1.97bn/$2.64bn), declining 13% from the previous quarter. Revenues ...

U.S. stock futures were up in early European trading following through on moves after the bell Tuesday on optimism around U.S.-China trade talks, while most European markets were down on EU tariff ...

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...

European stock markets are poised for a mixed and cautious opening on Wednesday as investors globally turn their full ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

India's film industry, which earns roughly 40% of its overseas revenue from the United States, sounded the alarm this week ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

The weight loss company will focus on its transition into a telehealth service that helps users get prescriptions for drugs ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...